USANA Health Sciences (USNA) Projected to Post Earnings on Tuesday

Key Points

• USANA will report Q1 2026 results after the market close on May 5, 2026, with analysts expecting EPS of $0.44 and revenue of $241.355 million; the earnings call is scheduled for May 6 at 11:00 AM ET.
• For context, USANA beat estimates in the prior quarter (EPS $0.60 vs. $0.41 expected); analysts forecast about $2 EPS for the current fiscal year and $3 for the next, but the shares trade around $19.44 with a market cap near $359 million and carry mixed analyst sentiment (average rating "Reduce").

USANA Health Sciences (NYSE:USNA - Get Free Report) is expected to release its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect USANA Health Sciences to post earnings of $0.44 per share and revenue of $241.3550 million for the quarter. Individuals may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 11:00 AM ET.

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The company reported $0.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.19. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. The company had revenue of $226.20 million for the quarter, compared to the consensus estimate of $225.96 million. On average, analysts expect USANA Health Sciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Stock Up 0.0%

Shares of NYSE:USNA opened at $19.44 on Tuesday. The firm has a fifty day simple moving average of $18.63 and a two-hundred day simple moving average of $19.76. USANA Health Sciences has a 52 week low of $16.60 and a 52 week high of $38.32. The stock has a market capitalization of $358.92 million, a P/E ratio of 35.35, a PEG ratio of 0.83 and a beta of 0.71.

Analyst Ratings Changes

Several research analysts recently commented on the company. Zacks Research lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 22nd. Wall Street Zen upgraded USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of USANA Health Sciences in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Reduce".

Insider Activity at USANA Health Sciences

In related news, insider Joshua Foukas sold 4,461 shares of the company's stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $21.34, for a total transaction of $95,197.74. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.82% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its stake in USANA Health Sciences by 4.6% in the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company's stock worth $244,000 after buying an additional 542 shares during the period. Quantbot Technologies LP lifted its holdings in USANA Health Sciences by 19.5% during the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock valued at $121,000 after buying an additional 646 shares in the last quarter. Intech Investment Management LLC boosted its position in USANA Health Sciences by 13.5% in the 3rd quarter. Intech Investment Management LLC now owns 7,722 shares of the company's stock valued at $213,000 after buying an additional 918 shares during the period. National Bank of Canada FI boosted its position in USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company's stock valued at $53,000 after buying an additional 1,201 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company's stock worth $106,000 after acquiring an additional 1,327 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company's stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.